Phase II Study in Patients With Operable Breast Cancer
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.
Breast Cancer
DRUG: Pegylated Liposomal Doxorubicin (Doxil)
Identify the pCR rate of neoadjuvant chemotherapy using the proposed 18-week regimen of PLD + paclitaxel + trastuzumab, within 18 weeks
Identify the complete response rate, within 18 weeks|Identify the partial response rate, within 18 weeks|Identify the overall response rate, within 18 weeks|Evaluate changes in cardiac function, within study participation|Monitor safety and tolerability of neoadjuvant chemotherapy using the proposed 18 week regimen, within study participation
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.